Skip to main content
Legit Tirzepatide

The reputation and the record

Tirzepatide references: the record behind the reputation

The reading list includes discovery work, clinical comparisons, withdrawal studies, safety reviews and regulatory records.

The papers I’d lay on the table first

The discovery paper supplies the molecule’s beginnings. SURMOUNT-1 establishes the placebo-controlled weight result; SURMOUNT-5 directly compares tirzepatide with semaglutide in obesity. SURMOUNT-4 tests withdrawal. The body-composition substudy looks inside the weight change rather than treating every lost pound as fat.

For diabetes, SURPASS-2 is the direct semaglutide comparison. For safety, the pancreatitis and biliary review and the prescribing information do different work: one pools trials, the other records the label’s warnings and exclusions. I would not ask either source to stand in for the other.

Research resources are not reference material for a preparation

“Tirzepatide reference standard” and “tirzepatide reference material” can mean an analytical material used to identify or measure a substance. This page is a reading list. It cannot authenticate a preparation or substitute for a laboratory test report.

Tirzepatide claims data, adverse-event reports and randomized trials likewise need distinct interpretations. A database of submitted safety reports can reveal a signal; it cannot by itself establish causation or a population-wide event rate. The effects entry follows that problem.

Searches for reçetesiz tirzepatide concern access without a prescription. The current regulatory record describes approved tirzepatide formulations as prescription-only. Legit Tirzepatide provides research resources, not access to medicines.

The full reading list

The list below retains the published records used across this site. Some are regulatory documents or broad reviews, while others report a specific experiment. The research entry brings the clinical results together; the identity entry follows the earlier laboratory work.

Source register

  1. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. ↗
  2. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. ↗
  3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. ↗
  4. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. ↗
  5. Heerspink HJL, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial. Lancet Diabetes Endocrinol. 2022. ↗
  6. U.S. Food and Drug Administration. Tirzepatide injection prescribing information (FDA label). FDA Drugs@FDA. 2022. ↗
  7. Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. ↗
  8. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. ↗
  9. Horn DB, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2026. ↗
  10. Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. ↗
  11. Hammoud R, et al. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023. ↗
  12. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. ↗
  13. Dahl D, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-5). Lancet. 2021. ↗
  14. Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. ↗
  15. Batsis JA, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Ann Intern Med. 2026. ↗
  16. Safwan M, et al. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Ann Saudi Med. 2025. ↗
  17. Mishra R, et al. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-analysis. Cureus. 2023. ↗
  18. Shen P, et al. Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis. PLoS One. 2026. ↗
  19. Kunutsor SK, et al. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. Drugs. 2026. ↗
  20. Farzam K, Patel P. Tirzepatide (StatPearls). StatPearls [Internet], NCBI Bookshelf. 2024. ↗
  21. Gong J, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis. J Diabetes Investig. 2025. ↗
  22. Nassar M, et al. Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis. Diabetes Metab Syndr. 2024. ↗
  23. Zhang Z, et al. Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database. Endocr Connect. 2025. ↗
  24. Jalleh RJ, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024. ↗
  25. Urva S, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020. ↗
  26. et al. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. Cureus. 2025. ↗
  27. Qazi S, et al. Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2026. ↗
  28. U.S. Food and Drug Administration. FDA approval for chronic weight management (tirzepatide) — press announcement and label record. FDA News & Events. 2023. ↗
  29. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025. ↗
  30. Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. ↗
  31. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). N Engl J Med. 2025. ↗
  32. de la Cruz-Concepcion B, et al. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27. Hypertension. 2024. ↗
  33. Rasouli N, et al. Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials. Diabetes Ther. 2025. ↗
  34. Campbell JE, et al. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab. 2023. ↗
  35. Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024. ↗
  36. Almansour HA, et al. Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025). Healthcare (Basel). 2025. ↗
  37. Berg S, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes Rev. 2025. ↗
  38. Galli M, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025. ↗